.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,868,176

« Back to Dashboard

Details for Patent: 7,868,176

Title:Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N'-(4-(2-methylprop- yloxy)phenylmethyl)carbamide and their preparation
Abstract: Disclosed herein are salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide including the citrate, fumarate, maleate, malate, phosphate, succinate, sulphate, and edisylate salts.
Inventor(s): Thygesen; Mikkel Boas (Copenhagen East, DK), Schlienger; Nathalie (Frederiksberg, DK), Tolf; Bo-Ragnar (Malmo, SE), Blatter; Fritz (Reinach, CH), Berghausen; Jorg (Lorrach, DE)
Assignee: ACADIA Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:Sep 26, 2005
Application Number:11/235,381
Claims:1. An isolated and purified crystalline salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)ph- enylmethyl)carbamide of formula I, ##STR00032## wherein the salt is the citrate or edisylate salt.

2. The salt of claim 1, wherein the salt is a citrate.

3. The salt of claim 2 that exhibits a X-ray powder diffraction pattern comprising peaks having d-values in angstroms of about 31.8, about 15.9, about 7.9, about 6.3, about 5.96, about 5.23, and about 4.68.

4. The salt of claim 1, wherein the salt is an edisylate (ethanedisulfonate).

5. The salt of claim 4 that exhibits a X-ray powder diffraction pattern comprising peaks having d-values in angstroms of about 10.0, about 6.05, about 5.31, about 4.97, about 4.26, and about 4.12.

6. A crystalline salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)ph- enylmethyl)carbamide of formula I, ##STR00033## produced by a process comprising: a) forming a solution of the compound of formula I in an organic solvent; b) adding citric acid or 1,2-ethane disulfonic acid to said solution; and c) isolating the salt.

7. A pharmaceutical composition comprising one or more salts of claim 1 and a pharmaceutically acceptable carrier.

8. The phatinaceutical composition of claim 7, wherein the composition is in a solid dosage form.

9. The pharmaceutical composition of claim 8, wherein the solid dosage form is suitable for oral administration.

10. The pharmaceutical composition of claim 9, wherein the amount of the salt of formula IV is from about 1 to 100 mg.

11. The salt of claim 2 that exhibits a X-ray powder diffraction pattern comprising peaks having d-values in angstroms of about 15.9, about 7.9, about 6.3, and about 4.68.

12. The salt of claim 4 that exhibits a X-ray powder diffraction pattern comprising peaks having d-values in angstroms of about 10.0, about 6.05, and about 4.97.

13. The citrate salt of claim 2, wherein the salt is of formula IV: ##STR00034##

14. The edisylate salt of claim 4, wherein the salt is of formula XI: ##STR00035##

15. The citrate salt of claim 2, wherein the salt has a water solubility of about 14 mg/mL.

16. The edisylate salt of claim 4, wherein the salt has a water solubility of about 4 mg/mL.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc